Q&A: Philips on game-changing innovation and responsible AI at JPM
Shez Partovi, chief innovation and strategy officer at Philips, discussed the helium-free BlueSeal MRI and AI advances in a sit down with MobiHealthNews at JPM.
Related Articles
Fish implanted with tumor cells could help oncologists quickly personalize cancer treatments
The first clinical trial of zebrafish embryos acting as cancer “avatars” will start soon
Nanoscopy Unravels the Interplay Between Antibodies and CD20 in Immunotherapy
Researchers have developed a new microscopic method to observe the interactions of therapeutic antibodies with target molecules on tumor cells.
FTC: Big 3 PBMs generated $7.3B from specialty generic drug markups
CVS Caremark, Express Scripts and OptumRx dramatically mark up specialty generic drugs to affiliated pharmacies, the Federal Trade Commission (FTC) uncovered in its second interim…
Medtronic achieves renal denervation reimbursement milestone with CMS
Medtronic says CMS is opening a national coverage analysis on renal denervation (RDN) procedures for patients with hypertension.
Is obesity a disease? Not always, new expert report says
A more scientific definition of obesity should guide decisions about weight loss treatment, researchers argue
CIO Spotlight: Trinity Rehabilitation Services’ Robert Latz
He discusses the particular cybersecurity challenges for post-acute care settings, and previews a HIMSS25 session that will help IT leaders at nursing homes, home health…
5 emerging specialties among ASCs
“Discover the top specialties moving towards ASCs according to L.E.K. Consulting’s 2024 ASC Insights Study, including urology, orthopedics, and more.”
11 states adding the most ASCs
“Discover the top states with the highest increase in ASCs, including California, Florida, and Georgia. CMS reports a 3.5% growth in Medicare-certified ASCs acr
Breaking Boundaries in Spatial Biology: Exploring the 2D and 3D Landscape
© 2025 Mary Ann Liebert, Inc. Publishers. All rights reserved.
Industry Voices—Why the great unraveling of PBMs will accelerate in 2025
The pharmaceutical supply chain is a sector infamous for glacially slow adjustments, lackluster reform, lack of transparency and massive anti-competitive conglomerates.